1 Min Read
May 8 (Reuters) -
* FDA grants fast track designation to Xylocor Therapeutics lead candidate XC001
* An IND for XC001 is open with FDA and Xylocor intends to commence clinical trials upon funding Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.